cGAS mRNA-Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Messenger RNA (mRNA) vaccines are effective for immunization but lack adjuvants to enhance immune responses.
• Adjuvants are crucial for boosting vaccine efficacy against viral diseases and cancer.

Purpose of the Study:

• To develop a novel adjuvant using cyclic GMP-AMP synthase (cGAS) mRNA complexed with lipid nanoparticles (LNPs).
• To enhance the immune response and vaccine potency, particularly for cancer immunotherapy.

Main Methods:

• Engineered human cGAS mRNA (hcGASK187N/L195R) with specific mutations to increase cGAS activity.
• Complexed the modified mRNA with LNPs to create cGAS mRNA-LNPs.
• Evaluated the adjuvant effects in vitro and in vivo, assessing immune cell activation and vaccine potentiation.

Main Results:

• Mutated cGAS mRNA-LNPs significantly enhanced STING-mediated IFN response.
• Demonstrated potentiation of antigen-presenting cell functions and amplified humoral and cell-mediated immunity.
• Showcased significant antitumor immunity and direct tumor cell restriction via IFNγ.

Conclusions:

• Developed a cGAS mRNA-based immunostimulatory adjuvant compatible with various vaccine platforms.
• The adjuvant effectively boosts adaptive immune responses and enhances cancer immunotherapies.
• This approach offers a promising strategy for improving vaccine efficacy and cancer treatment.